0001736243 false 0001736243 2022-06-07 2022-06-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares






Washington, D.C. 20549





Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): June 7, 2022


Acurx Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)


Delaware  001-40536  82-3733567
(State or other jurisdiction
of incorporation)
File Number)

(IRS Employer

Identification No.)


259 Liberty Avenue, Staten Island, NY 10305

(Address of principal executive offices) (Zip Code)


Registrant’s telephone number, including area code: (917)533-1469


Not applicable

(Former name or former address, if changed since last report.)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class   Trading
  Name of each exchange
on which registered
Common Stock, par value $0.001 per share   ACXP   The Nasdaq Stock Market LLC


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company  x


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨







Item 5.07 Submission of Matters to a Vote of Security Holders.


At the Annual Meeting of Acurx Pharmaceuticals, Inc. (“we”, “us” and “our”) held on June 7, 2022, the holders of 5,689,473 shares of our common stock, or approximately 55.43% of our outstanding shares of common stock, were represented in person or by proxy and, therefore, a quorum was present. At the Annual Meeting, our stockholders considered two proposals, which are described briefly below and in more detail in the Proxy Statement. The final voting results for each proposal are set forth below.


Proposal 1 – Election of Directors


Our stockholders elected the following directors as Class I directors to hold office until the 2025 Annual Meeting of stockholders by the following votes:


Nominees  Shares Voted
Carl V. Sailer  3,743,543  289,750  1,656,180
Thomas Harrison  3,741,578  291,715  1,656,180


Proposal 2 – Ratification of Independent Registered Public Accounting Firm


Our stockholders ratified the appointment of CohnReznick LLP as our independent auditors for the fiscal year ending December 31, 2022 by the following votes:


Shares Voted For  Shares Voted Against  Abstentions  Broker Non-Votes
5,584,342  98,801  6,330 







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed by the undersigned hereunto duly authorized.


  Acurx Pharmaceuticals, Inc.
Date: June 7, 2022    
  By: /s/ David P. Luci
  Name: David P. Luci
  Title: President and Chief Executive Officer